|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | In the name of the rose:a roadmap for rose research in the genome era显示文摘The recent completion of the rose genome sequence is not the end of a process,but rather a starting point that opens up a whole set of new and exciting activities.Next to a high-quality genome sequence other genomic tools have also become available for rose,including transcriptomics data,a high-density single-nucleotide polymorphism array and software to perform linkage and quantitative trait locus mapping in polyploids.Rose cultivars are highly heterogeneous and diverse.This vast diversity in cultivated roses can be explained through the genetic potential of the genus,introgressions from wild species into commercial tetraploid germplasm and the inimitable efforts of historical breeders.We can now investigate how this diversity can best be exploited and refined in future breeding work,given the rich molecular toolbox now available to the rose breeding community.This paper presents possible lines of research now that rose has entered the genomics era,and attempts to partially answer the question that arises after the completion of any draft genome sequence:‘Now that we have“the”genome,what’s next?’.Having access to a genome sequence will allow both(fundamental)scientific and(applied)breeding-orientated questions to be addressed.We outline possible approaches for a number of these questions. | Marinus J.M.Smulders Paul Arens Peter M.Bourke Thomas Debener Marcus Linde Jan De Riek Leen Leus Tom Ruttink Sylvie Baudino Laurence Hibrant Saint-Oyant Jeremy Clotault Fabrice Foucher | 2019 | Horticulture Research2019，6，1： | 2 |
| 2 | Incretin therapy and its effect on body weight in patients with diabetes显示文摘 | Marcus Lind | 2012 | Primary Care Diabetes2012，，3： | 1 |
| 3 | Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction显示文摘 | Marcus Lind Johan Jendle Ole Torffvit Ibe Lager | 2011 | Primary Care Diabetes2011，，1： | 1 |
| 4 | D-dimer predicts major bleeding, cardiovascular events and all-cause mortality during warfarin treatment显示文摘 | Marcus Lind Kurt Boman Lars Johansson Torbj?rn K. Nilsson Lisbeth Slunga J?rvholm Jan-H?kan Jansson | 2014 | Clinical Biochemistry2014，，： | 1 |
| 5 | Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction显示文摘 | Marcus Lind Johan Jendle Ole Torffvit Ibe Lager | 2011 | Primary Care Diabetes2011，，1： | 1 |
| 6 | Performance of Dexcom G5 and FreeStyle Libre sensors tested simultaneously in people with type 1 or 2 diabetes and advanced chronic kidney disease显示文摘BACKGROUND Advanced chronic kidney disease(CKD) is a common complication for people with type 1 and 2 diabetes and can often lead to glucose instability. Continuous glucose monitoring(CGM) helps users monitor and stabilize their glucose levels. To date, CGM and intermittent scanning CGM are only approved for people with diabetes but not for those with advanced CKD.AIM To compare the performance of Dexcom G5 and FreeStyle Libre sensors in adults with type 1 or 2 diabetes and advanced CKD.METHODS This was a non-randomized clinical trial that took place in two outpatient clinics in western Sweden. All patients with type 1 or 2 diabetes and an estimated glomerular filtration rate(eGFR) of < 30 mL/min per 1.73 m^(2) were invited to participate. Forty patients(full analysis set = 33) carried the Dexcom G5 sensor for 7 d and FreeStyle Libre sensor for 14 d simultaneously. For referencing capillary blood glucose(SMBG) was measured with a high accuracy glucose meter(HemoCue®) during the study period. At the end of the study, all patients were asked to answer a questionnaire on their experience using the sensors.RESULTS The mean age was 64.1(range 41-77) years, hemoglobin A1 c was 7.0% [standard deviation(SD) 3.2], and diabetes duration was 28.5(SD 14.7) years. A total of 27.5% of the study population was on hemodialysis and 22.5% on peritoneal dialysis. The mean absolute relative difference for Dexcom G5 vs SMBG was significantly lower than that for FreeStyle Libre vs SMBG [15.2%(SD 12.2) vs 20.9%(SD 8.6)], with a mean difference of 5.72 [95% confidence interval(CI): 2.11-9.32;P = 0.0036]. The mean absolute difference was also significantly lower for Dexcom G5 than for FreeStyle Libre, 1.21 mmol/L(SD 0.78) and 1.76 mmol/L(SD 0.78), with a mean diffrenec of 0.55(95%CI: 0.27-0.83;P = 0.0004).The mean difference(MD) was-0.107 mmol/L and-1.10 mmol/L(P = 0.0002), respectively. In all, 66% of FreeStyle Libre values were in the no risk zone on the surveillance error grid compared to 82% of Dexcom G5 values.CONCLUSION Dexcom G5 produces more accurate sensor values than FreeStyle Libre in people with diabetes and advanced CKD and is likely safe to be used by those with advanced CKD. | Arndís FinnaÓlafsdóttir Mervi Andelin Aso Saeed Sheyda Sofizadeh Hussein Hamoodi Per-Anders Jansson Marcus Lind | 2022 | World Journal of Clinical Cases2022，10，22： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员